Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic, 'Very Disappointed,' Posts 26-Percent Slide in Q3 Revenue; Hires Bank to Help With Strategy

NEW YORK (GenomeWeb News) - Transgenomic today said third-quarter revenues decreased 26 percent as R&D spending rose 15 percent and income turned swung to a loss.
Total receipts for the three months ended Sept. 30 decreased to $4.9 million from $6.7 million year over year.
"We were very disappointed in our sales," CEO and President Craig Tuttle said. The company added that it has hired Thomas Weisel Partners to help it figure out how to “maximize shareholder value” in the short- and long-term.
"The typical market slowdown during summer in Europe was larger this year for our WAVE system than in years past and coincided with an unusual shortfall in system sales in Asia," he added. 
R&D spending increased to $586,000 from $510,000 year over year.
The company said it racked up $1.7 million in net losses in the quarter from a profit of $111,000 in the year-ago period.
Transgenomic said it had around $7.3 million in cash and cash equivalents as of Sept. 30.
Tuttle said he expects a better fourth quarter, partly because some sales came in too late in the third quarter to make the third-quarter report, and because of new products, including an application for standard sequencing platforms.
Tuttle also said he hopes that future revenue will come from intellectual property for cancer-linked mutations that he said the company recently discovered.

The Scan

Test of the China Initiative

According to Science, the upcoming trial of Harvard University chemist Charles Lieber will test the US China Initiative.

Collaborative Approach

A virologist who spotted the Omicron variant of SARS-CoV-2 tells the Associated Press that its detection was aided by scientific sharing.

Genes of a Guide Dog

Wired reports on a study aimed at uncovering genes involved in being a successful guide dog.

PLOS Papers on RNAs in Metastatic Prostate Cancer, Ebola Field Lab, Embryonic RNA Editing

In PLOS this week: circRNA-mediated ceRNA network points to prostate cancer biomarkers, Ebola testing at frontline field laboratory, and more.